HyperlipidemiaPhase 3NCT00362206
Comparison of the Combination of Fenofibrate and Simvastatin Versus Pravastatin
A Phase 3 study testing Fenofibrate/Simvastatin and Pravastatin in people with Hyperlipidemia, run by Solvay Pharmaceuticals at 41 sites in 5 countries.
Trial summary
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia.The overall objective of the study is to compare the efficacy and… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Hyperlipidemia
- What is being tested?
- Fenofibrate/Simvastatin and Pravastatin
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 423 participants
- Where
- 41 sitesin 5 countries
- Study dates
- Sep 2006to Sep 2008
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Mixed dyslipidemia
Who cannot join
- Known hypersensitivity to fenofibrates or simvastatin or pravastatin
- Pregnant or lactating women
- Contra-indication to fenofibrate or simvastatin or pravastatin
- Unstable or severe cardiac disease
Trial locations and contacts
41 sites in 5 countries.
41 sites in 5 countries
South Africa13 sites
Site 10
Alberton
Site 9
Bloemfontein
Site 14
Cape Town
Site 35
Durban
Site 36
eMkhomazi
Site 33
Hillcrest
Site 34
Kempton Park
Site 16
Komatipoort
Site 13
Krugersdorp
Site 11
Parow
Site 12
Port Elizabeth
Site 8
Pretoria
Site 15
Worcester
Israel10 sites
Site 37
Beer Yaakov
Site 19
Haifa
Site 22
Holon
Site 18
Jerusalem
Site 38
Kfar Saba
Site 17
Ramat Gan
Site 21
Ramat Gan
Site 20
Rehovot
Site 24
Safed
Site 23
Tel Aviv
Russia8 sites
Site 27
Barnaul
Site 31
Kemerovo
Site 32
Krasnoyarsk
Site 25
Moscow
Site 28
Novosibirsk
Site 29
Saint Petersburg
Site 26
Smolensk
Site 30
Voronezh
Romania7 sites
Site 5
Arad
Site 7
Bacau
Site 1
Bucharest
Site 6
Cluj-Napoca
Site 4
Oradea
Site 3
Ploieşti
Site 2
Târgu Mureş
About this study
Official title: A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Pravastatin Alone
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia.The overall objective of the study is to compare the efficacy and safety of combining fenofibrate and simvastatin versus pravastatin monotherapy in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
- Conditions
- Hyperlipidemia
- Being tested
- Fenofibrate/Simvastatin, Pravastatin
- Keywords
- Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin versus pravastatin, Hyperlipidemia Combined
- Medical subject headings
- Hyperlipidemias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Fenofibrate/SimvastatinDrug
Combination of Fenofibrate and Simvastatin 20mg
Fenofibrate/SimvastatinDrug
Combination of Fenofibrate and Simvastatin 40 mg
PravastatinDrug
Pravastatin 40 mg
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: Fenofibrate/Simvastatin |
| 2 | Experimental | Not described Receives: Drug: Fenofibrate/Simvastatin |
| 3 | Active comparator | Not described Receives: Drug: Pravastatin |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent change from baseline to 12 weeks of treatment in Triglycerides
Measured: 12 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
Measured: 12 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
Measured: 12 weeks
Secondary outcomes (3)
Percent change from baseline to 12 weeks of treatment in Triglycerides
Measured: 24 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
Measured: 24 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
Measured: 24 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2006 (estimated)
- Study startSep 2006
- Primary completionSep 2008
- Study completionSep 2008
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HyperlipidemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 423 participants (actual)
Sponsor and investigators
- Lead sponsor
- Solvay Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Investigators
- Global Clinical Director Solvay, Study director, Solvay Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00362206
- Sponsor's protocol ID
- C LF0242780-01 05 04
- Other IDs
- 2006-000515-15
- Status last verified
- Jul 2009
- First submitted
- 8 Aug 2006
- Last updated
- 8 Jul 2009
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Multicenter, Double-Blind, Randomized, Forced-Titration Study to Compare the Efficacy and Safety of the Combination of 145 mg Fenofibrate and 20 or 40 mg Simvastatin With 40 mg Pravastatin Monotherapy in Patients With Mixed Dyslipidemia at Risk of Cardiovascular Disease Not Adequately Controlled by 40 mg Pravastatin Alone
- ClinicalTrials.gov ID
- NCT00362206
- Acronym / sponsor ID
- C LF0242780-01 05 04
- Conditions
- Hyperlipidemia
- Keywords
- Hyperlipidemia Combined, efficacy combination fenofibrate simvastatin versus pravastatin, Hyperlipidemia Combined
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 423 participants (actual)
- Lead sponsor
- Solvay PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Sep 2006
- Primary completion
- Sep 2008 (actual)
- Study completion
- Sep 2008 (actual)
- First posted
- 9 Aug 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Mixed or combined hyperlipidemia is a common metabolic disorder characterized by both hypercholesterolemia and hypertriglyceridemia. Statins and fibrates have complementary mechanisms and can be coadministered to patients with mixed hyperlipidemia.The overall objective of the study is to compare the efficacy and safety of combining fenofibrate and simvastatin versus pravastatin monotherapy in patients with mixed hyperlipidemia at risk of cardiovascular diseases.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Fenofibrate/Simvastatin |
| 2 | Experimental | Drug: Fenofibrate/Simvastatin |
| 3 | Active comparator | Drug: Pravastatin |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (1 listed)
- Mixed dyslipidemia
Key exclusion criteria (4 listed)
- Known hypersensitivity to fenofibrates or simvastatin or pravastatin
- Pregnant or lactating women
- Contra-indication to fenofibrate or simvastatin or pravastatin
- Unstable or severe cardiac disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Fenofibrate/SimvastatinCombination of Fenofibrate and Simvastatin 20mg | Drug | 1 |
| Fenofibrate/SimvastatinCombination of Fenofibrate and Simvastatin 40 mg | Drug | 2 |
| PravastatinPravastatin 40 mg | Drug | 3 |
Primary outcome
Percent change from baseline to 12 weeks of treatment in Triglycerides
Time frame: 12 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
Time frame: 12 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
Time frame: 12 weeks
3 secondary outcomes
Percent change from baseline to 12 weeks of treatment in Triglycerides
Time frame: 24 weeks
Percent change from baseline to 12 weeks of treatment in HDL-C
Time frame: 24 weeks
Percent change from baseline to 12 weeks of treatment in LDL-C
Time frame: 24 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2009.
Related trials for Hyperlipidemia
Not yet recruiting
Plasma Lipids-Dependent Vitamin E Metabolism During Dynamic Hyperlipidemia
Lipid Metabolism Disorders
Active, not recruiting
Developing a Learning COmmunity to Increase eNgagemeNt and Enrollment in Cardiovascular Clinical Trials (CONNECT)
Cardiovascular Diseases, Hypertension
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingObservational study
Causes and Natural History of Dyslipidemias
Hypercholesterolemia, Atherosclerosis
Active, not recruitingObservational study
Early Detection of Familial Hypercholesterolaemia in Pre-school Children ( CzeCH-IT)
Familial Hypercholesterolaemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Global Clinical Director Solvay study director
Solvay Pharmaceuticals
41 sites in 5 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Fenofibrate/Simvastatin and Pravastatin in people with Hyperlipidemia, run by Solvay Pharmaceuticals at 41 sites in 5 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 41 sites in South Africa, Israel, Russia, Romania, Greece. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent change from baseline to 12 weeks of treatment in Triglycerides (time frame: 12 weeks). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2009.